Recent investigative reports indicate that a subset of Indian cricketers, including players participating in the Indian Premier League, are utilizing prescription glucagon-like peptide-1 receptor agonists—such as semaglutide-based Ozempic and tirzepatide-based Mounjaro—as a shortcut to achieve lean, athletic physiques inspired by benchmarks set by Virat Kohli.
Understanding GLP-1 Medications and Their Mechanism of Action
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of pharmaceutical treatments developed to manage Type 2 diabetes and, in certain cases, clinically defined obesity. The physiological mechanism of action relies on mimicking the endogenous hormone GLP-1, which is naturally released by the gut after a meal. This hormonal cascade signals the pancreas to produce insulin, slows the rate at which the stomach empties, and communicates with the brain to reduce appetite.
Because these peptides profoundly alter metabolic processing and caloric intake, they can induce rapid weight loss. However, medical consensus emphasizes that these compounds are potent therapies with specific indications and contraindications, rather than benign lifestyle supplements.
In Plain English: The Clinical Takeaway
- What they are: Prescription drugs like Ozempic and Mounjaro regulate blood sugar and slow digestion to treat diabetes and clinical obesity.
- The shortcut risk: Using these potent medications purely for cosmetic leanness bypasses normal physiological conditioning and exposes healthy bodies to unnecessary pharmacological risks.
- Market expansion: Increased availability of generic formulations and newer market entries have expanded regional access, raising concerns about unsupervised use outside clinical settings.
Regional Accessibility, Market Expansion, and Economic Shifts
The accessibility of these therapeutics has evolved rapidly across global and regional markets. In India, the therapeutic landscape shifted significantly following the market introduction of tirzepatide in March 2025, with pricing structures varying by dosage strength. Wegovy, a semaglutide formulation specifically indicated for weight management, entered the Indian market in June 2025, followed by generic semaglutide alternatives in March 2026 at substantially reduced price points.
This economic democratization of peptide drugs has widened availability far beyond traditional patient demographics.
| Generic Name | Primary Brand Examples | Primary Clinical Indication | Common Adverse Effects |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Type 2 Diabetes, Chronic Weight Management | Nausea, vomiting, diarrhea, constipation |
| Tirzepatide | Mounjaro | Type 2 Diabetes, Adjunct Weight Loss | Nausea, vomiting, diarrhea, constipation |
Contraindications & When to Consult a Doctor
Medical consultation is mandatory if an individual experiencing treatment exhibits symptoms such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, or bloating. Unsupervised cosmetic use outside of structured medical supervision bypasses critical safety screenings and diagnostic evaluations.
